Aldatu Biosciences, Inc. today announced that it has entered into a licensing agreement with Harvard University’s Office of Technology Development based on intellectual property developed in the laboratory of Professor Myron (Max) Essex, DVM, PhD, at the Harvard T.H. Chan School of Public Health.
Aldatu Biosciences Receives $1.5 Million Direct-to-Phase II SBIR Grant from the NIAID for HIV Drug Resistance Diagnostic Development
Cambridge, MA, 12th March 2015 (download press release .pdf) Aldatu Biosciences, a novel diagnostics platform company focused on improving HIV patient care globally, today announced it has been awarded a Direct-to-Phase …